Anidulafungin, VER002

Phase 2Small molecule

Pfizer

Anidulafungin, VER002 is one of 38 small molecule programs targeting Aspergillosis. It is currently in Phase 2.

Indications

Total Trials

Active Trials

Competitors

Pipeline

Status by Indication[3][1]

Indication

AspergillosisActive, not recruiting

CandidiasisActive, not recruiting

AspergillosisPhase 2/Phase 3

Active, not recruiting

CandidiasisPhase 2

Active, not recruiting

Competition

Competitive Landscape

48 competitors in Candidiasis

#DrugCompanyPhaseTrials

Diflucan

PPfizer's Upjohn has merged with Mylan to form Viatris Inc.

Approved

17 2

Mycamine

BBaxter Healthcare Corporation

Approved

12 3

Cancidas

FFresenius Kabi Oncology Ltd.

Approved

8 4

Eraxis

VVicuron Pharmaceuticals

Approved

4 5

Sporanox

SSebela Pharmaceuticals Development LLC

Approved

2 6

Vfend

PPrism Pharmaceuticals

Approved

2 7

Lotrimin

Bayer

Phase 3

1 8

Ambisome

Gilead

Approved

1 9

Mycostatin

GGood Molecules, LLC

Phase 3

2 10

Nizoral

WWim Janssens

Phase 3

Ranked by pipeline maturity and clinical activity. Current drug highlighted in teal.

Clinical

Trials by Indication[1]

Candidiasis2 trials

The Safety and Efficacy of Intravenous Anidulafungin as a Treatment for Azole-Refractory Mucosal Candidiasis (FRMC)

Completed· Pfizer logo

Pfizer·Phase 2·NCT00041704·19 enrolled

The Safety and Effectiveness of Intravenous Anidulafungin as a Treatment for Patients With Invasive Candidiasis.

Completed· Pfizer logo

Pfizer·Phase 2·NCT00037219·120 enrolled

Aspergillosis1 trial

A Safety & Effectiveness Study of Intravenous Anidulafungin With AmBisome® for Treatment of Invasive Aspergillosis (IA).

Completed· Pfizer logo

Pfizer·Phase 2/3·NCT00037206·30 enrolled

Sources

References

[1]
ClinicalTrials.gov — 3 trial records for Anidulafungin, VER002. U.S. National Library of Medicine, National Institutes of Health.
[2]
ChEMBL — Anidulafungin, VER002 compound record. European Bioinformatics Institute (EMBL-EBI).
[3]
Open Targets Platform — Drug–disease associations for Anidulafungin, VER002. EMBL-EBI & Wellcome Sanger Institute.
[4]
SEC EDGAR — Pfizer company filings. U.S. Securities and Exchange Commission.

Details

Drug Info

Quick Facts

Modality: Small molecule[2]
Highest Phase: Phase 2[1]
Company: Pfizer

Anidulafungin, VER002

Status by Indication[3][1]

Competitive Landscape

Trials by Indication[1]

Candidiasis2 trials

Aspergillosis1 trial

References

Drug Info

Quick Facts

Related News